The Use of DNA Microarrays to Assess Clinical Samples

The Transition from Bedside to Bench to Bedside

John A. Copland, Peter J. Davies, Gregory L. Shipley, Christopher G. Wood, Bruce A. Luxon, Randall Urban

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The advent of gene array technology brings the ability to classify disease states to the molecular level by examining changes in all mRNAs expressed in cells or tissues. Comparing changes in gene expression patterns between normal and diseased cells and/or tissues has elucidated unique subsets of genes identifiable to a specific disease. Already, new subclassifications of specific cancers have been discovered, belying that genomic profiling can uniquely distinguish a specific disease state and tissue of origin. This technology bestows the ability to examine global changes occurring in a cell or tissue(s), thereby allowing the elucidation of alterations in dysregulated biological, biochemical, and molecular events leading to disease states such as diabetes, hypertension, infertility, obesity, osteoporosis, and atherosclerosis. Furthermore, genomic profiling will lead to new molecular targets for the development of drug therapeutics. Futuristically, one could envision personalized patient therapies based upon identification of specific aberrant signaling pathways that can be targeted for drug therapy.

Original languageEnglish (US)
Pages (from-to)25-53
Number of pages29
JournalRecent Progress in Hormone Research
Volume58
DOIs
StatePublished - 2003

Fingerprint

Oligonucleotide Array Sequence Analysis
Technology
Infertility
Genes
Osteoporosis
Atherosclerosis
Obesity
Hypertension
Gene Expression
Drug Therapy
Messenger RNA
Therapeutics
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Endocrinology

Cite this

The Use of DNA Microarrays to Assess Clinical Samples : The Transition from Bedside to Bench to Bedside. / Copland, John A.; Davies, Peter J.; Shipley, Gregory L.; Wood, Christopher G.; Luxon, Bruce A.; Urban, Randall.

In: Recent Progress in Hormone Research, Vol. 58, 2003, p. 25-53.

Research output: Contribution to journalArticle

Copland, John A. ; Davies, Peter J. ; Shipley, Gregory L. ; Wood, Christopher G. ; Luxon, Bruce A. ; Urban, Randall. / The Use of DNA Microarrays to Assess Clinical Samples : The Transition from Bedside to Bench to Bedside. In: Recent Progress in Hormone Research. 2003 ; Vol. 58. pp. 25-53.
@article{e238e2f3337d43f3adda763fa8800ae4,
title = "The Use of DNA Microarrays to Assess Clinical Samples: The Transition from Bedside to Bench to Bedside",
abstract = "The advent of gene array technology brings the ability to classify disease states to the molecular level by examining changes in all mRNAs expressed in cells or tissues. Comparing changes in gene expression patterns between normal and diseased cells and/or tissues has elucidated unique subsets of genes identifiable to a specific disease. Already, new subclassifications of specific cancers have been discovered, belying that genomic profiling can uniquely distinguish a specific disease state and tissue of origin. This technology bestows the ability to examine global changes occurring in a cell or tissue(s), thereby allowing the elucidation of alterations in dysregulated biological, biochemical, and molecular events leading to disease states such as diabetes, hypertension, infertility, obesity, osteoporosis, and atherosclerosis. Furthermore, genomic profiling will lead to new molecular targets for the development of drug therapeutics. Futuristically, one could envision personalized patient therapies based upon identification of specific aberrant signaling pathways that can be targeted for drug therapy.",
author = "Copland, {John A.} and Davies, {Peter J.} and Shipley, {Gregory L.} and Wood, {Christopher G.} and Luxon, {Bruce A.} and Randall Urban",
year = "2003",
doi = "10.1210/rp.58.1.25",
language = "English (US)",
volume = "58",
pages = "25--53",
journal = "Recent Progress in Hormone Research",
issn = "0079-9963",
publisher = "The Endocrine Society",

}

TY - JOUR

T1 - The Use of DNA Microarrays to Assess Clinical Samples

T2 - The Transition from Bedside to Bench to Bedside

AU - Copland, John A.

AU - Davies, Peter J.

AU - Shipley, Gregory L.

AU - Wood, Christopher G.

AU - Luxon, Bruce A.

AU - Urban, Randall

PY - 2003

Y1 - 2003

N2 - The advent of gene array technology brings the ability to classify disease states to the molecular level by examining changes in all mRNAs expressed in cells or tissues. Comparing changes in gene expression patterns between normal and diseased cells and/or tissues has elucidated unique subsets of genes identifiable to a specific disease. Already, new subclassifications of specific cancers have been discovered, belying that genomic profiling can uniquely distinguish a specific disease state and tissue of origin. This technology bestows the ability to examine global changes occurring in a cell or tissue(s), thereby allowing the elucidation of alterations in dysregulated biological, biochemical, and molecular events leading to disease states such as diabetes, hypertension, infertility, obesity, osteoporosis, and atherosclerosis. Furthermore, genomic profiling will lead to new molecular targets for the development of drug therapeutics. Futuristically, one could envision personalized patient therapies based upon identification of specific aberrant signaling pathways that can be targeted for drug therapy.

AB - The advent of gene array technology brings the ability to classify disease states to the molecular level by examining changes in all mRNAs expressed in cells or tissues. Comparing changes in gene expression patterns between normal and diseased cells and/or tissues has elucidated unique subsets of genes identifiable to a specific disease. Already, new subclassifications of specific cancers have been discovered, belying that genomic profiling can uniquely distinguish a specific disease state and tissue of origin. This technology bestows the ability to examine global changes occurring in a cell or tissue(s), thereby allowing the elucidation of alterations in dysregulated biological, biochemical, and molecular events leading to disease states such as diabetes, hypertension, infertility, obesity, osteoporosis, and atherosclerosis. Furthermore, genomic profiling will lead to new molecular targets for the development of drug therapeutics. Futuristically, one could envision personalized patient therapies based upon identification of specific aberrant signaling pathways that can be targeted for drug therapy.

UR - http://www.scopus.com/inward/record.url?scp=0041307017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041307017&partnerID=8YFLogxK

U2 - 10.1210/rp.58.1.25

DO - 10.1210/rp.58.1.25

M3 - Article

VL - 58

SP - 25

EP - 53

JO - Recent Progress in Hormone Research

JF - Recent Progress in Hormone Research

SN - 0079-9963

ER -